Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

FDA Approves Nivolumab (Opdivo) for Small Cell Lung Cancer

Published: Fri, 17 Aug 2018 14:10:12 EDT
The new approval is accelerated and is therefore conditional upon further proof of efficacy, but the checkpoint inhibitor becomes the first approved option in advanced SCLC in a long time.
FDA Approvals

Aug 17, 2018 This Week in Cardiology

Published: Fri, 17 Aug 2018 13:47:08 EDT
Screening athletes, AF ablation complications, physician gender and MI mortality, the rise of chronic kidney disease, and the rosuvastatin lawsuit are discussed in this week's podcast. on Medscape

FDA Clears Brain Stimulation Device for OCD

Published: Fri, 17 Aug 2018 13:29:53 EDT
The Brainsway deep transcranial magnetic stimulation system is an option for patients with obsessive-compulsive disorder (OCD) who have not responded to traditional treatments.
FDA Approvals

FDA Clears New Treatment for Dry Eye (Cequa)

Published: Fri, 17 Aug 2018 13:07:08 EDT
Cequa is a patented, novel, proprietary nanomicellar formulation of cyclosporine A in a clear, preservative-free, aqueous solution.
FDA Approvals
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


Sirnaomics cleared to start first trial of RNAi lead in cancer

Published: Fri, 17 Aug 2018 12:55:55 +0000
Gene-silencing specialist Sirnaomics has been cleared to start trials of its STP705 drug in bile duct cancer, its first oncology indication.

Novo buys Ziylo for glucose-responsive insulin platform

Published: Fri, 17 Aug 2018 11:25:59 +0000
Novo Nordisk has bought Ziylo to fuel its work on next-generation insulins. The takeover gives Novo control of a platform that could support development of insulins that respond to glucose.

Hubert Chen resigns as Pfenex CMO ahead of NDA

Published: Fri, 17 Aug 2018 07:33:06 +0000
Hubert Chen, M.D., has resigned as CMO of Pfenex. The imminent departure leaves Pfenex without a CMO as it gears up to file a new drug application (NDA), although Chen will continue to advise the biotech as it interacts with the FDA.

Chutes & Ladders—Gilead CMO to quit 6 months after taking the job

Published: Thu, 16 Aug 2018 16:27:27 +0000
Gilead's CMO Andrew Cheng quit six months after taking the job; Allergan tapped a Pfizer oncology veteran as CMO for some crucial pipeline help; and Novartis, reeling from the Michael Cohen scandal, recruited a Siemens veteran as its ethics chief. Those moves plus more hirings, firings and retirings throughout the industry.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy